Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
Condition(s) studied
Study summary
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression.
Genetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients.
In this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.
Eligibility
Primary outcome measure(s)
- PNPLA3 and MBOAT7 gene polymorphisms — 3 years after Liver Transplantation
To assess the impact of donor and recipient PNPLA3 and MBOAT7 gene polymorphisms on the development and severity of graft steatosis following Living Donor Liver Transplantation
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Institute of Liver and Biliary Sciences | New Delhi | India | Recruiting |
More Institute of Liver and Biliary Sciences, India trials in India
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07685353 on ClinicalTrials.gov ↗ ← All trials in India